Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
| dc.contributor.author | Cui, Haozhe | |
| dc.contributor.author | Elkord, Eyad | |
| dc.date.accessioned | 2025-09-16T04:43:36Z | |
| dc.date.available | 2025-09-16T04:43:36Z | |
| dc.date.issued | 2024 | |
| dc.description | According to a report in The Lancet, the factors affecting human mortality have essentially been the same from 1990 to the present. Excluding the impact of COVID-19 on human deaths in 2019–2021, the data show that cancer is one of the leading causes of mortality, along with cardiovascular disease and chronic obstructive pulmonary disease (COPD) [1]. The traditional approach against tumors is to remove the diseased tissue through surgery, as well as radiation and chemotherapy, but the limitations are also clear; they are only effective in the early stage of the disease and have potential to cause multiple side effects by damaging autologous healthy cells [2,3]. With the development of molecular biology, a significant milestone in tumor therapy is shifting the focus from tissues and organs to molecular mechanisms and the tumor microenvironment (TME) [4]. | |
| dc.description.abstract | The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs) targeting TIGIT are hopefully expected to address the issue of unresponsiveness to anti-PD-(L)1 monoclonal antibodies (mAbs) by combination therapy. This paper presents insights on the expression, structure and mechanism of action of TIGIT, as well as the principles and methods of designing mAbs targeting TIGIT and their clinical data. The advantages and disadvantages of targeting TIGIT using mAbs, bispecific and tri-specific antibodies (bsAbs and tsAbs), peptides, and compounds, in addition to potential combination therapies of anti-TIGIT with anti-PD-1 or cancer vaccines, are addressed. Finally, perspectives on current immunotherapies targeting TIGIT are discussed. Keywords: immune checkpoint, TIGIT, PD-1, antibody development, small-molecule therapy | |
| dc.identifier.citation | Cui, H., & Elkord, E. (2024). Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?. Vaccines, 12(12), 1306. | |
| dc.identifier.doi | https://doi.org/10.3390/vaccines12121306 | |
| dc.identifier.uri | https://repository.adu.ac.ae/handle/1/7468 | |
| dc.language.iso | en | |
| dc.publisher | MDPI | |
| dc.title | Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach? | |
| dc.type | Other |